Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Drug

Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China

Fineline Cube Aug 22, 2022

China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...

Company

Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial

Fineline Cube Aug 22, 2022

Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...

Company

Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B

Fineline Cube Aug 22, 2022

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022,...

Company Deals

JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products

Fineline Cube Aug 22, 2022

JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series...

Company Drug

IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China

Fineline Cube Aug 22, 2022

China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational...

Company

Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions

Fineline Cube Aug 22, 2022

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues...

Company Drug

Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC

Fineline Cube Aug 22, 2022

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Daiichi Sankyo’s Enhertu Accepted for Review in China for HER2-Low Breast Cancer

Fineline Cube Aug 19, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd,...

Policy / Regulatory

NHSA Proposes Regulations to Standardize Oral Implant Charges and Reduce Costs

Fineline Cube Aug 19, 2022

The National Healthcare Security Administration (NHSA) has released a draft proposal titled “Notice on Carrying...

Company Digital

Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth

Fineline Cube Aug 19, 2022

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company

WuXi STA Breaks Ground on New US Manufacturing Site in Delaware

Fineline Cube Aug 19, 2022

WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...

Company Deals

ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion

Fineline Cube Aug 19, 2022

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...

Company Drug

Zhejiang Erying’s Acetaminophen Set for CDE Priority Review in Pediatric Fever and Pain

Fineline Cube Aug 19, 2022

The Center for Drug Evaluation (CDE) has indicated that Zhejiang Erying Pharmaceutical Co., Ltd’s acetaminophen...

Company

Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing

Fineline Cube Aug 19, 2022

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...

Company Deals

LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development

Fineline Cube Aug 19, 2022

LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...

Company Drug

Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China

Fineline Cube Aug 19, 2022

Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...

Company Deals

mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC

Fineline Cube Aug 19, 2022

Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...

Company Deals

Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market

Fineline Cube Aug 19, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply...

Company Drug

Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine

Fineline Cube Aug 19, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...

Company Deals

Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion

Fineline Cube Aug 19, 2022

China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization...

Posts pagination

1 … 664 665 666 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.